Effect of fullerenol C60(OH)24 on lipid peroxidation of kidneys, testes and lungs in rats treated with doxorubicine

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 4, 2012, Pages 301-307

  Vapa, Ivana ^a   Torres, Vukosava Milic ^b   Djordjevic, Aleksandar ^a   Vasovic, Velibor ^a   Srdjenovic, Branislava ^a   Simic, Viktorija Dragojevic ^c   Popović, Jovan K ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c DEPARTMENT OF TOXICOLOGY   (Czech Republic)

Author keywords

Doxorubicin; Fullerenol; Lipid peroxidation; Reactive oxygen species

Indexed keywords

DOXORUBICIN; FULLERENE DERIVATIVE; FULLERENOL; THIOBARBITURIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INTOXICATION; HOMOGENATE; KIDNEY; KIDNEY HOMOGENATE; LIPID PEROXIDATION; LIVER HOMOGENATE; LUNG; LUNG HOMOGENATE; MALE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; RAT; SINGLE DRUG DOSE; SPECTROPHOTOMETRY; TESTIS; TESTIS DISEASE; TESTIS HOMOGENATE; TREATMENT INDICATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FULLERENES; KIDNEY; LIPID PEROXIDATION; LUNG; MALE; RATS; RATS, WISTAR; TESTIS;

EID: 84871297285     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-012-0092-y     Document Type: Article

References (36)

1. Allen NS, Zeynalov EB, Taylor K, Birkett P (2009) Antioxidant capacity of novel amine derivatives of buckminsterfullerene: Determination of inhibition rate constants in a model oxidation system. Polym Degrad Stab 94:1932-1940
2. Andrievsky GV, Bruskov VI, Tykhomyrov AA, Gudkov SV (2009) Peculiarities of the antioxidant and radioprotective effects of hydrated C60 fullerene nanostructures in vitro and in vivo. Free Radic Biol Med 47:786-793
3. Atessahin A, Karahan I, Turk G, Gur S, Yilmaz S, Ceribasi AO (2006) Protective role of lycopene on cisplatin-induced changes in sperm characteristics, testicular damage and oxidative stress in rats. Reprod Toxicol 21(1):42-47
4. Bogdanovic G, Kojic V, Djordjevic A, Canadanovic-Brunet J, Vojinovic-Miloradov M, Baltic V (2004) Modulating activity of fullerenol C60(OH)22 on doxorubicin-induced cytotoxicity. Toxicol In Vitro 18:629-637
5. Braden CV, Deman A, Ceyssens B, Pauwels M, Empsen C, Verbeelen D (2002) Vitamin E protects renal antioxidant enzymes and attenuates glomerulosclerosis in adriamycin treated rates. Nephron 91:129-133
6. Burton GW, Traber MG (1990) Vitamin E: Antioxidant activity, biokinetics and bioavailability. Annu Rev Nutr 10:357-363
7. Chen YW, Hwang KC, Yen CC, Lai YL (2004) Fullerene derivatives protect against oxidative stress in RAW 264.7 cells and ischemia reperfused lungs. An J Fiziol Regul Integr Comp Physiol 287:21-26
8. Conklin AK (2005) Coenzime Q 10 for prevention of anthracycline induced cardiotoxicity. Cancer Ther 4:110-130
9. Djordjevic A, Vojinovic-Miloradov M, Petranovic N, Deverski A, Lazar D, Ribar B (1998) Catalytic preparation and characterization of C60Br24. Fuller Sci Technol 6:689-694
10. Djordjevic A, Canadanovic-Brunet J, Vojnovic-Miloradov M, Bogdanovic G (2005) Antioxidant properties and hypothetical radical mechanism of fullerenol C60(OH)24. Oxid Commun 27:806-812
11. Djordjevic A, Bogdanovic G, Dobric S (2006) Fullerenes in biomedicine. J BUON 11:391-404
12. Dugan LL, Gabrielsen JK, Yu SP (1996) Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol Dis 3:129-135
13. Dugan LL, Turetsky DM, Du C et al (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 94:9434-9439
14. Dugan LL, Lovett EG, Quick J et al (2001) Fullerene based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 7:243-246
15. Gao J, Wang Y, Folta KM, Krishna V, Bai W, Indeglia P et al (2011) Polyhydroxy fullerenes (fullerols or fullerenols): Beneficial effects on growth and lifespan in diverse biological models. PLoS ONE 6:1-7
16. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharm Sci Inc 57:728-734
17. Gharbi N, Pressac M, Hadchouel M et al (2005) [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett 5(12):2578-2585
18. Gokcimen A, Cim A, Tola HT, Bayram D, Kocak A, Ozguner F, Ayata A (2007) Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicity. Hum Exp Toxicol 26(6):519-525
19. Kang JK, Lee YJ, No KO, Jung EY, Sung JH, Kim YB, Nam SY (2002) Ginseng intestinal metabolite-I (GIM-I) reduces doxorubicin toxicity in the mouse testis. Reprod Toxicol 16(3):291-298
20. Kinnula VL, Fattman CL, Tan RJ, Oury TD (2005) A possible role of redox modulatory therapy, "Oxidative stress in pulmonary fibrosis". Am J Respir Crit Care Med 172:417-422
21. Krusic PJ, Waserman E, Keizer PN et al (1991) Radical reaction of C60. Science 254:1183-1185
22. Lai YL, Murugan P, Hwang KC (2003) Fullerene derivate attenuates ischemia-reperfusion-induced lung injury. Life Sci 72:1271-1278
23. Li T, Danelisen I, Bello-Klein A, Singal PK (2000) Effects of probucol on changes of antioxidant enzymes in adriamycininduced cardiomyopathy in rats. Cardiovasc Res 46(523):530
24. Minoti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharm Rev 56(2):185-229
25. Mirkov S, Djordejvic A, Andric N et al (2004) Nitric-oxide scavenging activity of polyhydroxylated fullerenol. Nitric Oxide Biol Chem 11:201-207
26. Murugan MA, Gangadharan B, Mathur PP (2002) Antioxidative effect of fullerenol on goat epididymal spermatozoa. Asian J Androl 4:149-152
27. Olson HM, Capen CC (1977) Subacute cardiotoxicity of adriamycin in the rat. Biochemical and ultrastructural investigations. Lab Investig 37:386-394
28. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 4:3076-3086
29. Stroo WE, Olson RD, Boerth RC (1985) Efficacy of sulfhydryl compounds as inhibitors of iron dependent doxorubicin enhanced lipid peroxidation. Res Commun Chem Pathol Pharmacol 48:291-303
30. Torres VM, Srdjenovic B, Jacevic V, Simic VD, Djordjevic A, Simplício AL (2010) Fullerenol C60(OH)24 prevents doxorubicin-induced acute cardiotoxicity in rats. Pharmacol Rep 62(4):707-718
31. Trajkovic S, Dobric S, Djordjevic A (2005) Radioprotective efficiency of fullerenol in irradiated mice. Mater Sci Forum 494:549-554
32. Uchyama M, Mihara M (1978) Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86:271-278
33. Venditti P, Balestrieri M, De Leo T, Di Meo S (1998) Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res 38(3):695-702
34. Venkatesan N, Punithavathi D, Arumugam V (2000) Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 129:231-234
35. Yldrim Z, Sogut S, Odaci E, Iraz M, Ozyurt M, Kotuk M et al (2003) Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 47:149-156
36. Zima T, Tesar V, Crkovska J, Stejskalova A, Platenik J, Teminova J, Nemecek K, Janebova M, S tipek S (1998) ICRF-187 (dexrazoxan) protects from adriamycin induced nephrotic syndrome in rats. Nephrol Dial Transplant 13:1975-1979